PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33238842-7 2021 Mutant p53 reactivation with a new class of zinc metallochaperones (ZMC) that restore WT p53 structure and function by restoring Zn2+ to Zn2+ deficient mutant p53. Zinc 129-133 tumor protein p53 Homo sapiens 7-10 33238842-7 2021 Mutant p53 reactivation with a new class of zinc metallochaperones (ZMC) that restore WT p53 structure and function by restoring Zn2+ to Zn2+ deficient mutant p53. Zinc 129-133 tumor protein p53 Homo sapiens 89-92 33238842-7 2021 Mutant p53 reactivation with a new class of zinc metallochaperones (ZMC) that restore WT p53 structure and function by restoring Zn2+ to Zn2+ deficient mutant p53. Zinc 129-133 tumor protein p53 Homo sapiens 89-92 33238842-7 2021 Mutant p53 reactivation with a new class of zinc metallochaperones (ZMC) that restore WT p53 structure and function by restoring Zn2+ to Zn2+ deficient mutant p53. Zinc 137-141 tumor protein p53 Homo sapiens 7-10 33238842-7 2021 Mutant p53 reactivation with a new class of zinc metallochaperones (ZMC) that restore WT p53 structure and function by restoring Zn2+ to Zn2+ deficient mutant p53. Zinc 137-141 tumor protein p53 Homo sapiens 89-92 33238842-7 2021 Mutant p53 reactivation with a new class of zinc metallochaperones (ZMC) that restore WT p53 structure and function by restoring Zn2+ to Zn2+ deficient mutant p53. Zinc 137-141 tumor protein p53 Homo sapiens 89-92 30230059-2 2018 The common p53 mutation Y220C causes local protein unfolding, aggregation, and can result in a loss of Zn in the DNA-binding domain. Zinc 103-105 tumor protein p53 Homo sapiens 11-14 32042215-7 2019 While ZnO-NPs caused depletion of both wild-type and gain-of-function (GOF) mutant p53 protein in ovarian cancer cells, their ability to induce apoptosis was found to be independent of the p53-mutation status in these cells. Zinc 6-9 tumor protein p53 Homo sapiens 83-86 31379409-8 2019 In addition, sublethal treatment with PAM induced phosphorylation of ATM kinase, accumulation of p53 protein, and expression of p21 and GADD45A, which are known p53 target genes, in a Zn2+-dependent manner. Zinc 184-188 tumor protein p53 Homo sapiens 97-100 31379409-8 2019 In addition, sublethal treatment with PAM induced phosphorylation of ATM kinase, accumulation of p53 protein, and expression of p21 and GADD45A, which are known p53 target genes, in a Zn2+-dependent manner. Zinc 184-188 tumor protein p53 Homo sapiens 161-164 31379409-9 2019 These results suggest that the induction of growth arrest and cellular senescence by sublethal PAM treatment is mediated by Zn2+-dependent activation of the ATM/p53 pathway. Zinc 124-128 tumor protein p53 Homo sapiens 161-164 30230059-5 2018 Their Zn-binding affinity was characterized using spectroscopic methods and demonstrate the ability of compounds L4 and L5 to increase intracellular levels of Zn2+ in a p53-Y220C-mutant cell line. Zinc 159-163 tumor protein p53 Homo sapiens 169-172 26493598-6 2015 We then show that U87- p53 inactivity can be rescued by zinc (Zn). Zinc 62-64 tumor protein p53 Homo sapiens 23-26 27195669-11 2016 Despite similar p53 activation profiles, these data revealed widespread dampening of p53 and NRF2-related genes as early as 4 h after exposure at higher, unrecoverable Zn2+ exposures. Zinc 168-172 tumor protein p53 Homo sapiens 85-88 27567443-7 2016 Zn supplementation (IC50=15muM), increased significantly CDKN2A, pRB1 & p53 and markedly reduced mdm2 expression; also protein expression levels of CDKN2A and pRb1 was significantly increased. Zinc 0-2 tumor protein p53 Homo sapiens 76-79 26205328-5 2015 Here, we describe recent work defining a new class of drugs termed zinc metallochaperones that restore WT p53 structure and function by restoring Zn(2+) to Zn(2+)-deficient mutant p53. Zinc 146-148 tumor protein p53 Homo sapiens 106-109 26205328-5 2015 Here, we describe recent work defining a new class of drugs termed zinc metallochaperones that restore WT p53 structure and function by restoring Zn(2+) to Zn(2+)-deficient mutant p53. Zinc 146-148 tumor protein p53 Homo sapiens 180-183 26205328-5 2015 Here, we describe recent work defining a new class of drugs termed zinc metallochaperones that restore WT p53 structure and function by restoring Zn(2+) to Zn(2+)-deficient mutant p53. Zinc 156-158 tumor protein p53 Homo sapiens 106-109 26205328-5 2015 Here, we describe recent work defining a new class of drugs termed zinc metallochaperones that restore WT p53 structure and function by restoring Zn(2+) to Zn(2+)-deficient mutant p53. Zinc 156-158 tumor protein p53 Homo sapiens 180-183 26297485-0 2015 The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells. Zinc 25-33 tumor protein p53 Homo sapiens 84-87 26314369-0 2015 Zn(II)-curc targets p53 in thyroid cancer cells. Zinc 0-6 tumor protein p53 Homo sapiens 20-23 26314369-5 2015 Here, we investigated whether Zn(II)-curc could affect p53 in thyroid cancer cells with both p53 mutation (R273H) and wild-type p53. Zinc 30-36 tumor protein p53 Homo sapiens 55-58 26314369-8 2015 In addition, Zn(II)-curc triggered p53 target gene expression in wild-type p53-carrying cells. Zinc 13-19 tumor protein p53 Homo sapiens 35-38 26314369-8 2015 In addition, Zn(II)-curc triggered p53 target gene expression in wild-type p53-carrying cells. Zinc 13-19 tumor protein p53 Homo sapiens 75-78 26314369-10 2015 Taken together, our data indicate that Zn(II)-curc promotes the reactivation of p53 in thyroid cancer cells, providing in vitro evidence for a potential therapeutic approach in thyroid cancers. Zinc 39-45 tumor protein p53 Homo sapiens 80-83 26297485-0 2015 The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells. Zinc 25-33 tumor protein p53 Homo sapiens 112-115 24874727-4 2014 We have previously reported that Zn(II) restores a folded conformation from mutp53 misfolding, rescuing wild-type (wt) p53/DNA-binding and transcription activities. Zinc 33-39 tumor protein p53 Homo sapiens 79-82 25002230-4 2014 We report herein on the radioprotective activity of 8-hydroxyquinoline (8HQ) derivatives that were initially designed so as to interact with the Zn(2+) in p53. Zinc 145-147 tumor protein p53 Homo sapiens 155-158 25710967-1 2015 p53 is a Zn(2+)-dependent tumor suppressor inactivated in >50% of human cancers. Zinc 9-11 tumor protein p53 Homo sapiens 0-3 25710967-6 2015 These [Zn(2+)]free levels are predicted to result in ~90% saturation of p53-R175H, thus accounting for its observed reactivation. Zinc 7-13 tumor protein p53 Homo sapiens 72-75 24874727-9 2014 Mechanistically, Zn(II) restored the wtp53 ability to induce the expression of the p53 target gene DRAM (damage-regulated autophagy modulator), a key regulator of autophagy, leading to autophagic induction. Zinc 17-23 tumor protein p53 Homo sapiens 39-42 22766626-6 2012 We found that zinc(II) ions caused elevated expression of Ki-67, a marker of proliferation, extremely low expression of p53, high expression of Bcl-2 and no changes in the expression of p53. Zinc 14-22 tumor protein p53 Homo sapiens 132-135 23652223-9 2012 Cadmium has also been shown to replace Zn in the tumor suppressor protein, p53 thereby impairing p53"s DNA binding activity and associated repair processes. Zinc 39-41 tumor protein p53 Homo sapiens 75-78 23652223-9 2012 Cadmium has also been shown to replace Zn in the tumor suppressor protein, p53 thereby impairing p53"s DNA binding activity and associated repair processes. Zinc 39-41 tumor protein p53 Homo sapiens 97-100 24280450-0 2013 Evaluation of zinc (II) chelators for inhibiting p53-mediated apoptosis. Zinc 14-23 tumor protein p53 Homo sapiens 49-52 24280450-9 2013 Our findings indicate that the use of zinc (II) chelators represent a new approach for protecting against radiation-induced p53-dependent apoptosis through the inhibition of p53-dependent apoptotic pathways. Zinc 38-47 tumor protein p53 Homo sapiens 124-127 24280450-9 2013 Our findings indicate that the use of zinc (II) chelators represent a new approach for protecting against radiation-induced p53-dependent apoptosis through the inhibition of p53-dependent apoptotic pathways. Zinc 38-47 tumor protein p53 Homo sapiens 174-177 23401182-2 2013 A number of previous studies have shown that zinc (Zn) modulates mitogenic activity via several signalling pathways, such as AKT, mitogen-activated protein kinase (MAPK), nuclear factor-kappa B (NF -kappaB), AP-1 and p53. Zinc 51-53 tumor protein p53 Homo sapiens 217-220 23401182-4 2013 Intracellular free Zn modulates p53 activity and stability, and excess Zn alters the p53 protein structure and down-regulates p53"s binding to DNA. Zinc 71-73 tumor protein p53 Homo sapiens 85-88 23401182-4 2013 Intracellular free Zn modulates p53 activity and stability, and excess Zn alters the p53 protein structure and down-regulates p53"s binding to DNA. Zinc 71-73 tumor protein p53 Homo sapiens 85-88 23401182-6 2013 Cu can also displace Zn from its normal binding site on p53, resulting in abnormal protein folding and disruption of p53 function. Zinc 21-23 tumor protein p53 Homo sapiens 56-59 23401182-6 2013 Cu can also displace Zn from its normal binding site on p53, resulting in abnormal protein folding and disruption of p53 function. Zinc 21-23 tumor protein p53 Homo sapiens 117-120 22803791-0 2013 The substitutions G245C and G245D in the Zn(2+)-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain. Zinc 41-47 tumor protein p53 Homo sapiens 70-73 22803791-3 2013 We have previously obtained an evidence that amino acid substitutions in the p53 Zn(2+)-binding pocket can presumably exert an influence on Zn(2+) position in the Zn(2+)-p53 complex and thereby affect p53 binding to DNA. Zinc 81-87 tumor protein p53 Homo sapiens 77-80 22803791-3 2013 We have previously obtained an evidence that amino acid substitutions in the p53 Zn(2+)-binding pocket can presumably exert an influence on Zn(2+) position in the Zn(2+)-p53 complex and thereby affect p53 binding to DNA. Zinc 81-87 tumor protein p53 Homo sapiens 170-173 22803791-3 2013 We have previously obtained an evidence that amino acid substitutions in the p53 Zn(2+)-binding pocket can presumably exert an influence on Zn(2+) position in the Zn(2+)-p53 complex and thereby affect p53 binding to DNA. Zinc 81-87 tumor protein p53 Homo sapiens 170-173 22803791-3 2013 We have previously obtained an evidence that amino acid substitutions in the p53 Zn(2+)-binding pocket can presumably exert an influence on Zn(2+) position in the Zn(2+)-p53 complex and thereby affect p53 binding to DNA. Zinc 81-83 tumor protein p53 Homo sapiens 77-80 22803791-3 2013 We have previously obtained an evidence that amino acid substitutions in the p53 Zn(2+)-binding pocket can presumably exert an influence on Zn(2+) position in the Zn(2+)-p53 complex and thereby affect p53 binding to DNA. Zinc 81-83 tumor protein p53 Homo sapiens 170-173 22803791-3 2013 We have previously obtained an evidence that amino acid substitutions in the p53 Zn(2+)-binding pocket can presumably exert an influence on Zn(2+) position in the Zn(2+)-p53 complex and thereby affect p53 binding to DNA. Zinc 81-83 tumor protein p53 Homo sapiens 170-173 22803791-3 2013 We have previously obtained an evidence that amino acid substitutions in the p53 Zn(2+)-binding pocket can presumably exert an influence on Zn(2+) position in the Zn(2+)-p53 complex and thereby affect p53 binding to DNA. Zinc 140-142 tumor protein p53 Homo sapiens 77-80 22803791-3 2013 We have previously obtained an evidence that amino acid substitutions in the p53 Zn(2+)-binding pocket can presumably exert an influence on Zn(2+) position in the Zn(2+)-p53 complex and thereby affect p53 binding to DNA. Zinc 140-142 tumor protein p53 Homo sapiens 170-173 22803791-3 2013 We have previously obtained an evidence that amino acid substitutions in the p53 Zn(2+)-binding pocket can presumably exert an influence on Zn(2+) position in the Zn(2+)-p53 complex and thereby affect p53 binding to DNA. Zinc 140-142 tumor protein p53 Homo sapiens 170-173 22803791-4 2013 With these background considerations, our aim was to estimate the effect of the putative changes in the Zn(2+) position in its binding pocket due to the G245C and G245D substitutions on the conformation of the p53 DNA-binding motif. Zinc 104-106 tumor protein p53 Homo sapiens 210-213 22803791-6 2013 MD simulations demonstrated that (1) the two substitutions in the Zn(2+)-binding pocket caused changes in the conformation of the p53 DNA-binding motif, as compared with the wild-type (WT) p53; (2) binding of Zn(2+) to the p53 mutant forms reduced the effect of the substitutions on conformational change; and (3) Zn(2+) binding in the normal position compensated the effect of the mutations on the conformation in comparison to the altered Zn(2+) position. Zinc 66-68 tumor protein p53 Homo sapiens 130-133 22803791-6 2013 MD simulations demonstrated that (1) the two substitutions in the Zn(2+)-binding pocket caused changes in the conformation of the p53 DNA-binding motif, as compared with the wild-type (WT) p53; (2) binding of Zn(2+) to the p53 mutant forms reduced the effect of the substitutions on conformational change; and (3) Zn(2+) binding in the normal position compensated the effect of the mutations on the conformation in comparison to the altered Zn(2+) position. Zinc 66-68 tumor protein p53 Homo sapiens 189-192 22803791-6 2013 MD simulations demonstrated that (1) the two substitutions in the Zn(2+)-binding pocket caused changes in the conformation of the p53 DNA-binding motif, as compared with the wild-type (WT) p53; (2) binding of Zn(2+) to the p53 mutant forms reduced the effect of the substitutions on conformational change; and (3) Zn(2+) binding in the normal position compensated the effect of the mutations on the conformation in comparison to the altered Zn(2+) position. Zinc 66-68 tumor protein p53 Homo sapiens 189-192 22803791-6 2013 MD simulations demonstrated that (1) the two substitutions in the Zn(2+)-binding pocket caused changes in the conformation of the p53 DNA-binding motif, as compared with the wild-type (WT) p53; (2) binding of Zn(2+) to the p53 mutant forms reduced the effect of the substitutions on conformational change; and (3) Zn(2+) binding in the normal position compensated the effect of the mutations on the conformation in comparison to the altered Zn(2+) position. Zinc 209-211 tumor protein p53 Homo sapiens 130-133 22803791-6 2013 MD simulations demonstrated that (1) the two substitutions in the Zn(2+)-binding pocket caused changes in the conformation of the p53 DNA-binding motif, as compared with the wild-type (WT) p53; (2) binding of Zn(2+) to the p53 mutant forms reduced the effect of the substitutions on conformational change; and (3) Zn(2+) binding in the normal position compensated the effect of the mutations on the conformation in comparison to the altered Zn(2+) position. Zinc 209-211 tumor protein p53 Homo sapiens 130-133 22803791-6 2013 MD simulations demonstrated that (1) the two substitutions in the Zn(2+)-binding pocket caused changes in the conformation of the p53 DNA-binding motif, as compared with the wild-type (WT) p53; (2) binding of Zn(2+) to the p53 mutant forms reduced the effect of the substitutions on conformational change; and (3) Zn(2+) binding in the normal position compensated the effect of the mutations on the conformation in comparison to the altered Zn(2+) position. Zinc 209-211 tumor protein p53 Homo sapiens 130-133 22427690-5 2012 Furthermore, the Zn(+2) region conformational p53 mutants (p53(R175H) and p53(H179R)) induced the CGS by elevating H-Ras activity. Zinc 17-19 tumor protein p53 Homo sapiens 46-49 22869710-4 2012 EDTA removes Zn(2+) to generate apo-p53, which aggregated faster than holo-p53. Zinc 13-15 tumor protein p53 Homo sapiens 36-39 22869710-6 2012 Apo-p53 was not an obligatory intermediate in the aggregation of holo-p53, but affords a parallel pathway that may be relevant to oncogenic mutants with impaired Zn(2+) binding. Zinc 162-168 tumor protein p53 Homo sapiens 4-7 22427690-5 2012 Furthermore, the Zn(+2) region conformational p53 mutants (p53(R175H) and p53(H179R)) induced the CGS by elevating H-Ras activity. Zinc 17-19 tumor protein p53 Homo sapiens 59-62 22427690-5 2012 Furthermore, the Zn(+2) region conformational p53 mutants (p53(R175H) and p53(H179R)) induced the CGS by elevating H-Ras activity. Zinc 17-19 tumor protein p53 Homo sapiens 59-62 21660051-5 2011 Silencing of GSK-3beta or p53 expression was cardioprotective, indicating that activation of the ERK-GSK-3beta-p53 signaling pathway is involved in Zn(2+)-sensitive myocyte death. Zinc 148-150 tumor protein p53 Homo sapiens 26-29 21935692-8 2012 Expression of PARP, p53 and OGG1 measured by western blotting was increased in Zn-depleted cells indicating that DNA repair mechanisms are activated. Zinc 79-81 tumor protein p53 Homo sapiens 20-23 21660051-5 2011 Silencing of GSK-3beta or p53 expression was cardioprotective, indicating that activation of the ERK-GSK-3beta-p53 signaling pathway is involved in Zn(2+)-sensitive myocyte death. Zinc 148-150 tumor protein p53 Homo sapiens 111-114 21780454-0 2011 Identification of p53 gene by using CdSe/ZnS conjugation and hybridization. Zinc 41-44 tumor protein p53 Homo sapiens 18-21 20660093-7 2010 These changes were normalized to those observed in ZN by treating ZS cells with Pifitherin, an inhibitor of p53 transactivation activity. Zinc 51-53 tumor protein p53 Homo sapiens 108-111 21076775-1 2011 Zn(2+) in the tumor-suppressor protein p53 DNA-binding domain (DBD) is essential for its structural stability and DNA-binding specificity. Zinc 0-2 tumor protein p53 Homo sapiens 39-42 21076775-8 2011 The simulation results of the Mg(2+) system and the native Zn(2+) system show that the binding affinity of Mg(2+)to the p53DBD is weaker than that of Zn(2+), in agreement with the DFT calculation results and experiments. Zinc 59-61 tumor protein p53 Homo sapiens 120-123 17848574-8 2007 MDM2 in which one of the Zn(2+) coordinating residues is mutated (C478S or C464A) blocks degradation but enhances folding of p53. Zinc 25-27 tumor protein p53 Homo sapiens 125-128 19681600-7 2009 Substitutions at Zn-coordinating cysteines C176, C238, or C242 resulted in p53 inactivation. Zinc 17-19 tumor protein p53 Homo sapiens 75-78 19805293-6 2009 The N-terminal 616 aa of CBP, which includes the conserved Zn(2+)-binding C/H1-TAZ1 domain, was the minimal domain sufficient to destabilize p53 in vivo, and it included within an intrinsic E3 autoubiquitination activity and, in a two-step E4 assay, exhibited robust E4 activity for p53. Zinc 59-65 tumor protein p53 Homo sapiens 141-144 18951928-5 2009 We show that Zn/PDTC induces p53 proteasomal degradation and that the proteasome inhibitor MG132 further increases fibroblast growth inhibition by Zn/PDTC, suggesting that p53 degradation plays an important role in fibroblast resistance to Zn/PDTC. Zinc 13-15 tumor protein p53 Homo sapiens 29-32 18951928-5 2009 We show that Zn/PDTC induces p53 proteasomal degradation and that the proteasome inhibitor MG132 further increases fibroblast growth inhibition by Zn/PDTC, suggesting that p53 degradation plays an important role in fibroblast resistance to Zn/PDTC. Zinc 13-15 tumor protein p53 Homo sapiens 172-175 18951928-5 2009 We show that Zn/PDTC induces p53 proteasomal degradation and that the proteasome inhibitor MG132 further increases fibroblast growth inhibition by Zn/PDTC, suggesting that p53 degradation plays an important role in fibroblast resistance to Zn/PDTC. Zinc 147-149 tumor protein p53 Homo sapiens 172-175 17297920-0 2007 Zn(2+)-dependent misfolding of the p53 DNA binding domain. Zinc 0-6 tumor protein p53 Homo sapiens 35-38 15242600-4 2004 However, three loops, involved in DNA and Zn binding in human p53, contain small alpha helices in Cep-1. Zinc 42-44 tumor protein p53 Homo sapiens 62-65 18415980-10 2007 Recently the G245C substitution has been assumed to result in formation of a novel Zn(2+)-binding site in the p53 protein. Zinc 83-89 tumor protein p53 Homo sapiens 110-113 16768444-0 2006 Effect of Zn2+ on DNA recognition and stability of the p53 DNA-binding domain. Zinc 10-14 tumor protein p53 Homo sapiens 55-58 16768444-3 2006 We have carried out molecular dynamics simulations to investigate the influence of Zn2+ on the p53 DNA recognition and the stability of the DBD. Zinc 83-87 tumor protein p53 Homo sapiens 95-98 16768444-8 2006 Our results suggest that L2 may be a frustrated and highly flexible element and play an important role in aggregation of Zn-free p53. Zinc 121-123 tumor protein p53 Homo sapiens 129-132 15163458-11 2004 CONCLUSIONS: This study provides evidence that redox-active (Fe2+), (Mn2+), (Cu2+), and (Zn2+) ion-induced apoptosis in PBL by (H2O2)/(.OH) generation, resulting in mitochondria depolarization, caspase-3 activation, and nuclear fragmentation independent of NF-kappaB and p53 transcription factors activation. Zinc 89-93 tumor protein p53 Homo sapiens 271-274 12686631-9 2003 Ehp53 also contains seven of the eight DNA-binding residues and two of the four Zn(2+)-binding sites described for p53. Zinc 80-86 tumor protein p53 Homo sapiens 2-5 12792793-13 2003 If white patients were stratified according to the type and location of TP53 mutations, patients with mutations affecting amino acids directly involved in DNA or Zn binding displayed a poor prognosis. Zinc 162-164 tumor protein p53 Homo sapiens 72-76 12107071-6 2002 Reducing [Zn(2+)](i), using N,N,N",N"-tetrakis(2-pyridylmethyl)ethylenediamine, caused rapid apoptosis in both p53(wt) and p53(mut) cells, although cotreatment with VP-16 exacerbated apoptosis only in p53(wt) cells. Zinc 10-16 tumor protein p53 Homo sapiens 111-114 12600206-11 2003 Through a combination of induced p53 aggregation and diminished site-specific DNA binding activity, Zn(2+) loss may represent a significant inactivation pathway for p53 in the cell. Zinc 100-106 tumor protein p53 Homo sapiens 33-36 12600206-11 2003 Through a combination of induced p53 aggregation and diminished site-specific DNA binding activity, Zn(2+) loss may represent a significant inactivation pathway for p53 in the cell. Zinc 100-106 tumor protein p53 Homo sapiens 165-168 12107071-6 2002 Reducing [Zn(2+)](i), using N,N,N",N"-tetrakis(2-pyridylmethyl)ethylenediamine, caused rapid apoptosis in both p53(wt) and p53(mut) cells, although cotreatment with VP-16 exacerbated apoptosis only in p53(wt) cells. Zinc 10-16 tumor protein p53 Homo sapiens 123-126 12107071-6 2002 Reducing [Zn(2+)](i), using N,N,N",N"-tetrakis(2-pyridylmethyl)ethylenediamine, caused rapid apoptosis in both p53(wt) and p53(mut) cells, although cotreatment with VP-16 exacerbated apoptosis only in p53(wt) cells. Zinc 10-16 tumor protein p53 Homo sapiens 123-126 12107071-8 2002 We conclude that the DNA damage-induced transient is p53-independent up to a damage threshold, beyond which competent cells reduce [Zn(2+)](i) before apoptosis. Zinc 132-138 tumor protein p53 Homo sapiens 53-56 12107071-9 2002 Early stress responses in p53(wt) cells take place in an environment of enhanced Zn(2+) availability. Zinc 81-87 tumor protein p53 Homo sapiens 26-29 9405613-6 1997 One Zn2+ ion remains tightly bound in the holo-form of p53 throughout the denaturation curve. Zinc 4-8 tumor protein p53 Homo sapiens 55-58 10604188-4 1999 In intact cells, p53 protein activity is crucially dependent on the availability of Zn ions and is impaired by exposure to Cd, a metal which readily substitutes for Zn in a number of transcription factors. Zinc 84-86 tumor protein p53 Homo sapiens 17-20 10604188-4 1999 In intact cells, p53 protein activity is crucially dependent on the availability of Zn ions and is impaired by exposure to Cd, a metal which readily substitutes for Zn in a number of transcription factors. Zinc 165-167 tumor protein p53 Homo sapiens 17-20 9485322-8 1998 In this paper, we report that S100B(beta beta) binds to the p53 peptide (CaK3 < or = 23.5 +/- 6.6 microM) in a Ca(2+)-dependent manner, and that the presence of the p53 peptide was found to increase the binding affinity of Ca2+ to S100B(beta beta) by 3-fold using EPR and PRR methods, whereas the peptide had no effect on Zn2+ binding to S100B(beta beta). Zinc 325-329 tumor protein p53 Homo sapiens 60-63 12095159-3 2002 Thus, this work explored the ability of Zn to protect human neurons in culture (NT2-N) from Cu-mediated death and tested the hypotheses that the tumor-suppressor protein p53 plays a role in Cu-induced neuronal death and is part of the mechanism of Zn protection. Zinc 248-250 tumor protein p53 Homo sapiens 170-173 12095159-5 2002 However, the addition of 700 microM Zn to Cu-treated cells resulted in neuronal viability that was not different from untreated controls through 24 h. p53 mRNA abundance, while increased by the addition of Cu and 100 microM Zn, was decreased to 50% of control with the addition of 500 microM Zn in Cu-treated cells, and to 10% of control with 700 microM Zn. Zinc 36-38 tumor protein p53 Homo sapiens 151-154 12095159-5 2002 However, the addition of 700 microM Zn to Cu-treated cells resulted in neuronal viability that was not different from untreated controls through 24 h. p53 mRNA abundance, while increased by the addition of Cu and 100 microM Zn, was decreased to 50% of control with the addition of 500 microM Zn in Cu-treated cells, and to 10% of control with 700 microM Zn. Zinc 224-226 tumor protein p53 Homo sapiens 151-154 12095159-5 2002 However, the addition of 700 microM Zn to Cu-treated cells resulted in neuronal viability that was not different from untreated controls through 24 h. p53 mRNA abundance, while increased by the addition of Cu and 100 microM Zn, was decreased to 50% of control with the addition of 500 microM Zn in Cu-treated cells, and to 10% of control with 700 microM Zn. Zinc 224-226 tumor protein p53 Homo sapiens 151-154 12095159-5 2002 However, the addition of 700 microM Zn to Cu-treated cells resulted in neuronal viability that was not different from untreated controls through 24 h. p53 mRNA abundance, while increased by the addition of Cu and 100 microM Zn, was decreased to 50% of control with the addition of 500 microM Zn in Cu-treated cells, and to 10% of control with 700 microM Zn. Zinc 224-226 tumor protein p53 Homo sapiens 151-154 12095159-8 2002 Furthermore, the addition of 500-700 microM Zn prevented the movement of p53 into the nucleus suggesting that Zn not only protects neurons from Cu toxicity by regulating p53 mRNA abundance but also by preventing the translocation of p53 to the nucleus. Zinc 44-46 tumor protein p53 Homo sapiens 73-76 12095159-8 2002 Furthermore, the addition of 500-700 microM Zn prevented the movement of p53 into the nucleus suggesting that Zn not only protects neurons from Cu toxicity by regulating p53 mRNA abundance but also by preventing the translocation of p53 to the nucleus. Zinc 44-46 tumor protein p53 Homo sapiens 170-173 12095159-8 2002 Furthermore, the addition of 500-700 microM Zn prevented the movement of p53 into the nucleus suggesting that Zn not only protects neurons from Cu toxicity by regulating p53 mRNA abundance but also by preventing the translocation of p53 to the nucleus. Zinc 44-46 tumor protein p53 Homo sapiens 170-173 12095159-8 2002 Furthermore, the addition of 500-700 microM Zn prevented the movement of p53 into the nucleus suggesting that Zn not only protects neurons from Cu toxicity by regulating p53 mRNA abundance but also by preventing the translocation of p53 to the nucleus. Zinc 110-112 tumor protein p53 Homo sapiens 73-76 12095159-8 2002 Furthermore, the addition of 500-700 microM Zn prevented the movement of p53 into the nucleus suggesting that Zn not only protects neurons from Cu toxicity by regulating p53 mRNA abundance but also by preventing the translocation of p53 to the nucleus. Zinc 110-112 tumor protein p53 Homo sapiens 170-173 12095159-8 2002 Furthermore, the addition of 500-700 microM Zn prevented the movement of p53 into the nucleus suggesting that Zn not only protects neurons from Cu toxicity by regulating p53 mRNA abundance but also by preventing the translocation of p53 to the nucleus. Zinc 110-112 tumor protein p53 Homo sapiens 170-173 22607421-7 2000 Compared to the intrinsic zinc strongly bound to Cys 176, Cys 238, Cys 242 and His 179 in the p53 core domain, binding of additional Zn(2+) to p53 was much weaker as shown by an easy removal of the latter ions by low concentrations of EDTA. Zinc 133-135 tumor protein p53 Homo sapiens 143-146 10487521-3 1999 To further elucidate the mechanism of growth suppression caused by p53-273L, we used squamous cell carcinoma cell line HSC3 to isolate subclones containing Zn2+-inducible wild-type (wt) p53, p53-175H, and p53-273L. Zinc 156-160 tumor protein p53 Homo sapiens 186-189 10487521-3 1999 To further elucidate the mechanism of growth suppression caused by p53-273L, we used squamous cell carcinoma cell line HSC3 to isolate subclones containing Zn2+-inducible wild-type (wt) p53, p53-175H, and p53-273L. Zinc 156-160 tumor protein p53 Homo sapiens 186-189 10487521-3 1999 To further elucidate the mechanism of growth suppression caused by p53-273L, we used squamous cell carcinoma cell line HSC3 to isolate subclones containing Zn2+-inducible wild-type (wt) p53, p53-175H, and p53-273L. Zinc 156-160 tumor protein p53 Homo sapiens 186-189 8552392-4 1996 Using the conformational domain of p53 fused with protein A, we have shown that the p53 conformational domain possesses Zn+2-dependent, sequence-specific DNA-binding activity. Zinc 120-124 tumor protein p53 Homo sapiens 84-87 8552392-4 1996 Using the conformational domain of p53 fused with protein A, we have shown that the p53 conformational domain possesses Zn+2-dependent, sequence-specific DNA-binding activity. Zinc 120-124 tumor protein p53 Homo sapiens 35-38 8055938-10 1994 Zn2+ binding to p53 protect sulfhydryl groups from oxidation. Zinc 0-4 tumor protein p53 Homo sapiens 16-19 7811703-3 1994 Our results show that the presence of Zn2+ ions at physiological concentrations, directly reduced or blocked accessibility of epitopes on pure wild-type p53, an effect which was reversed by chelating agents. Zinc 38-42 tumor protein p53 Homo sapiens 153-156 7811703-5 1994 Analytical sucrose density gradient ultracentrifugation studies also confirmed that Zn(2+)-induced conformational changes partially affected the pattern of p53 oligomerisation. Zinc 84-90 tumor protein p53 Homo sapiens 156-159 8168507-7 1994 Using metal affinity chromatography, we have established that pure p53 binds the immobilised divalent ions Zn2+, Ni2+ and Co2+ with high affinity. Zinc 107-111 tumor protein p53 Homo sapiens 67-70 35488931-9 2022 This includes understanding the relative populations of the Zn-bound and Zn-free p53 in wild-type and mutant forms, and the development of metallochaperones to re-populate the Zn binding site to restore mutant p53 activity. Zinc 176-178 tumor protein p53 Homo sapiens 210-213 35487360-7 2022 Therefore, a quantitative structure-activity relationship (QSAR) model was constructed to characterize the binding constants (Ka) between DNA binding domain of p53 (p53 DBD) and nine metal ions (Mg2+, Ca2+, Cu2+, Zn2+, Co2+, Ni2+, Mn2+, Fe3+ and Ba2+). Zinc 213-217 tumor protein p53 Homo sapiens 160-163 35487360-7 2022 Therefore, a quantitative structure-activity relationship (QSAR) model was constructed to characterize the binding constants (Ka) between DNA binding domain of p53 (p53 DBD) and nine metal ions (Mg2+, Ca2+, Cu2+, Zn2+, Co2+, Ni2+, Mn2+, Fe3+ and Ba2+). Zinc 213-217 tumor protein p53 Homo sapiens 165-168 35488931-5 2022 In this review, we will discuss the role of Zn in the proper function of the p53 protein in cancer. Zinc 44-46 tumor protein p53 Homo sapiens 77-80 35488931-9 2022 This includes understanding the relative populations of the Zn-bound and Zn-free p53 in wild-type and mutant forms, and the development of metallochaperones to re-populate the Zn binding site to restore mutant p53 activity. Zinc 60-62 tumor protein p53 Homo sapiens 81-84